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Introduction
Anaemia is a common condition in critically ill patients, and
RBC transfusions are often used in the treatment and
management of this patient population. In fact, one study
[1] reported that 25% of all critically ill patients received
RBC transfusions. Many laboratory studies [2–8] have
examined the physiological responses (ie compensatory
mechanisms) of the body to anaemia, which include the
following [9]: increased cardiac output, decreased blood
viscosity, capillary changes, increased oxygen extraction,
and other tissue adaptations to meet oxygen require-
ments. Although critically ill patients are affected by a
number of factors that predispose them to the adverse
consequences of anaemia, persistence of this condition is
of particular concern because it may cause the compen-
satory mechanisms in these patients to become impaired,
risking oxygen deprivation in vital organs [9]. However,
critically ill patients may also be at increased risk from the
adverse effects of RBC transfusions, such as pulmonary
oedema from volume overload, immune suppression
resulting in increased risk of infection, and microcircula-
tory injury from poorly deformable RBCs.
It is the aim of the present commentary to justify the state-
ment ‘Transfusing to normal haemoglobin concentration
will not improve outcome.’ If we define normal haemoglo-
bin as being greater than 115 g/l for women and greater
than 125 g/l for men, then there is no evidence in the liter-
ature to justify maintaining such high concentrations by
the use of RBC transfusions in any anaemic patient. There
may, however, be some debate about adopting a transfu-
sion threshold of 100 g/l, which is well below ‘normal’.
It has recently been shown [10] that critically ill patients
are able to tolerate lower levels of haemoglobin than was
previously believed. The practice of adhering to a lower
Commentary
Debate: Transfusing to normal haemoglobin levels will not
improve outcome
Gonzalo Alvarez, Paul C Hébert and Sharyn Szick
Department of Medicine, Ottawa Hospital, Ottawa, Ontario, Canada
Correspondence: Paul C Hébert, MD, FRCPC, MHSc(Epid), Department of Medicine, Ottawa Hospital General Campus, 501 Smyth Road, Box 201,
Ottawa, Ontario, K1H 8L6, Canada
Abstract
Recent evidence suggests that critically ill patients are able to tolerate lower levels of haemoglobin
than was previously believed. It is our goal to show that transfusing to a level of 100 g/l does not
improve mortality and other clinically important outcomes in a critical care setting. Although many
questions remain, many laboratory and clinical studies, including a recent randomized controlled trial
(RCT), have established that transfusing to normal haemoglobin concentrations does not improve
organ failure and mortality in the critically ill patient. In addition, a restrictive transfusion strategy will
reduce exposure to allogeneic transfusions, result in more efficient use of red blood cells (RBCs), save
blood overall, and decrease health care costs.
Keywords: anemia, hemoglobin concentration, red blood cells, transfusion, transfusion strategies
Received: 24 January 2001
Accepted: 21 February 2001
Published: 8 March 2001
Critical Care 2001, 5:56–63
© 2001 BioMed Central Ltd
(Print ISSN 1364-8535; Online ISSN 1466-609X)Available online http://ccforum.com/content/5/2/056
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
m
e
e
t
i
n
g
 
a
b
s
t
r
a
c
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
s
u
p
p
l
e
m
e
n
t
transfusion threshold would, obviously, reduce the number
of allogeneic RBCs transfused. It is our goal to impress
upon the reader that transfusing to a level equal to or
greater than 100 g/l does not improve mortality and other
clinically important outcomes in a critical care setting. We
first explore the reasons why a reduction in the total
number of allogeneic blood transfusions would be benefi-
cial. Second, we examine the current evidence for using a
lower transfusion strategy, specifically that employed in the
Transfusion Requirements In Critical Care (TRICC) trial.
Potential consequences of allogeneic red
blood cell transfusion
RBC transfusions have inherent risks that may be catego-
rized as follows [11–15]: transfusion-transmitted infec-
tions; immune-related reactions (acute or delayed
haemolytic reactions, febrile, allergic, anaphylactic reac-
tions and graft-versus-host disease); and nonimmune-
related reactions (fluid overload, hypothermia, electrolyte
toxicity and iron overload).
Major improvements in donor screening procedures and
laboratory testing have dramatically improved the safety of
the blood supply [16]. Currently, the risk of transmitting an
infectious agent through blood transfusion ranges from
1:100,000 for hepatitis B virus to 1:1,000,000 for HIV
(Canadian Blood Services, personal communication, 2000).
The most important threats to the blood supply remain new
and unknown pathogens. More recently, concern has
focused on the potential transmission of prions through
RBCs. Also, infectious agents with long latency periods
pose particular risks to young individuals who require
RBCs, such as multiple trauma victims. The risk : benefit
ratio for a 24-year-old trauma victim with a 50-year life
expectancy differs markedly from that for a person aged
80 years who is undergoing coronary artery bypass surgery.
In summary, because there is a risk of transmitting diseases
through the blood supply, we should always strive to use
RBCs according to the best available evidence in order to
ensure that we do more good than harm to our patients.
It is a long-standing observation [17–21] that blood trans-
fusions are associated with immune suppression. This
clinical phenomenon was first observed in renal transplant
patients who had received blood transfusions while on
dialysis before the transplant [22], and has been observed
repeatedly in transplant centres around the world [23,24].
Recently, Opelz et al [25] reported a multicentre clinical
trial in which all renal allograft recipients received modern
immunosuppressive regimens. Those patients who were
allocated to receive three allogeneic RBC units before
renal transplant had a 1-year graft survival rate of 90%, as
compared with 82% for patients who were not transfused
(P = 0.02). These data suggest that there are long-term
immunosuppressive effects following transfusion of non-
leukocyte-reduced allogeneic RBCs.
A large number of studies [26–34] have also suggested
that allogeneic transfusions accelerate cancer growth,
perhaps due to altered immune surveillance. These altered
immune responses after allogeneic RBC transfusions may
also predispose critically ill transfusion recipients to noso-
comial infections [35–40] and increased rates of multiple-
system organ failure [41], which may ultimately result in
higher mortality rates. However, most studies that exam-
ined the association between cancer recurrence and post-
operative infection after transfusion [42,43] only provided
weak causal inferences because of poor study design and
the lack of independence between allogeneic RBC trans-
fusions and the potential complication.
A recent meta-analysis [44] combined the results from
seven RCTs, and was unable to detect clinically important
decreases in mortality and postoperative infections. We
added the results of a new RCT by van de Watering et al
[45] to the above meta-analysis. The relative risk for all-
cause mortality was 1.05 (95% confidence interval
0.88–1.25), and was 1.10 (95% confidence interval
0.85–1.43) for postoperative infections. However, this
meta-analysis excluded two positive RCTs [40,46]
because of the significant statistical heterogeneity intro-
duced by these two studies. If all available RCTs are com-
bined, ignoring heterogeneity, then the relative risk
difference for postoperative infections across all studies is
1.60 (95% confidence interval 1.00–2.56; P = 0.05).
Thus, the available evidence suggests that universal
prestorage leukoreduction could have clinical effects that
range from none to decreasing rates of infection by as
much as 50% in high-risk patients. In summary, despite
convincing laboratory evidence and some supportive clini-
cal studies, the clinical significance of the immunosup-
pressive effects of allogeneic RBC transfusions have not
been clearly established [47]. More importantly, the
impact of a leukoreduction programme has not been
studied in a large population of patients who are expected
to have significant exposure to allogeneic RBCs.
The majority of complications from allogeneic RBC trans-
fusion, however, are no more frequent in the intensive care
setting than in other patient populations, with the possible
exception of pulmonary oedema, hypothermia and elec-
trolyte disturbance. Hypothermia and electrolyte distur-
bances occur most frequently with massive transfusions.
In critically ill patients, the optimal effective circulatory
volume may be difficult to determine, and as a conse-
quence pulmonary oedema may be a much more frequent
complication of RBC transfusion than in other patient pop-
ulations. This may explain the significantly higher rate of
pulmonary oedema in patients transfused using a thresh-
old of 100 g/l (5.3% in the restrictive transfusion group
versus 10.7% in the liberal transfusion group; P < 0.01),
as reported in the TRICC trial [10]. As an alternative expla-
nation, the more frequent use of RBCs might haveCritical Care    Vol 5 No 2 Alvarez et al
resulted in more frequent episodes of transfusion-related
acute lung injury in the liberal strategy group (7.7% in the
restrictive strategy versus 11.4% in the liberal strategy;
P = 0.06), as reported in the TRICC trial.
Clinical evidence is also insufficient to definitively establish a
correlation between the age of RBCs being transfused and
patient mortality; however, laboratory evidence has shown
many storage-related changes that may result in impairment
of blood flow and oxygen delivery at the microcirculatory
level. Marik et al [48] demonstrated an association between
a fall in gastric intramucosal pH and transfusion of RBCs
stored for longer than 15 days. In addition, there is ample
laboratory evidence that prolonged RBC storage adversely
affects RBCs, potentially results in the generation of
cytokines, and alters host immune function. In another
study, Fitzgerald et al [49], using an animal model of transfu-
sion, consistently observed a lack of efficacy of transfused,
stored rat blood to improve tissue oxygen consumption as
compared with fresh cells or other blood substitutes.
Three retrospective clinical studies tested the association
between the age of transfused blood and duration of stay
in the intensive care unit (ICU) [50] and mortality [51,52].
Martin et al [50] observed a statistically significant associa-
tion between the transfusion of aged blood (>14 days old)
and increased duration of ICU stay (P = 0.003) in 698 criti-
cally ill patients. In patients who received a transfusion,
aged RBCs was the only predictor of duration of stay
(P < 0.0001). In survivors, only median age of blood was
predictive of duration of stay (P < 0.0001). Purdy et al [51]
demonstrated a negative correlation (r = –0.73) between
the proportion of RBC units of a given age transfused to
survivors and increasing age of RBCs in patients admitted
to the ICU with a diagnosis of severe sepsis (n = 31).
Those investigators also noted that these latter units were
more likely to be older. A recently reported study by Vam-
vakas and Carven [52] evaluated the effect of duration of
RBC storage on postoperative pneumonia in 416 consec-
utive patients undergoing coronary artery bypass grafting.
Those investigators noted an adjusted increase of 1% in
the risk of postoperative pneumonia per day of average
increase in the duration of RBC storage (P < 0.005) in
transfused patients. Each of these three studies also noted
that patients who received a large number of RBC units
had a higher mortality. Although these risks are relatively
small when viewed collectively, they become significant
when one considers that 25% of all critically ill patients in
Canada are transfused during their ICU stay [1].
Transfusion strategies
Until recently, physicians have depended on clinical judge-
ment when deciding at what haemoglobin level to trans-
fuse a critically ill patient. As a result, significant variation
has been shown to exist in transfusion practice among
Canadian critical care physicians [53], which is due
largely to a lack of published data on the subject. An arbi-
trary haemoglobin level of 100 g/l has historically been
used as a threshold to transfuse critically ill patients.
Six observational studies investigated the importance of
anaemia on transfusion practices in various settings. Of
these, three large cohort studies, which were performed in
different patient populations (intensive care [1], coronary
artery bypass surgery [54] and hip fractures [55]), reached
different conclusions. RBC transfusions in particular
improved outcome in critically ill patients with cardiovascu-
lar disease, but increased the risk of myocardial infarction
in coronary artery bypass surgery patients. Transfusion had
no impact on short-term or long-term mortality in hip-frac-
ture patients. Three smaller studies [56–58] evaluated the
relationship between anaemia and adverse outcomes in
vascular disease patients. Although increased numbers of
ischaemic events were observed in anaemic patients, the
validity of these studies is uncertain, given that the decision
to transfuse a patient was often correlated with illness
burden of the patient. It is also possible that comorbidity
was not adequately adjusted for in those studies.
Transfusion thresholds were compared in 10 randomized
clinical trials [10,59–67]. Although the clinical settings
varied, each trial randomized patients to be transfused on
the basis of a ‘conservative’ or a ‘liberal’ strategy. The defini-
tions of conservative and liberal strategies varied, and actu-
ally overlapped between studies. Of these 10 trials, only
three included more than 100 patients and only one trial
evaluated the impact of transfusion on symptoms. In the first
trial of patients undergoing elective coronary artery bypass
surgery [65], the differences between perioperative haemo-
globin levels were small, event rates were very low, and
there were no differences in any outcome. In the second
trial [67], patients undergoing knee arthroplasty were ran-
domly assigned to receive autologous blood transfusion
immediately after surgery or to receive autologous blood if
haemoglobin level fell below 9 g/dl [67]. Again, no differ-
ences in outcome were observed. The third trial of hip frac-
ture patients undergoing surgical repair [64] found no
differences in outcomes; however, five deaths were
recorded at 60 days after surgery in the symptomatic group,
and two deaths occurred in the 10 g/dl group. The numbers
of patients in these trials were too small to evaluate the
effect of lower transfusion triggers on clinically important
outcomes such as mortality, morbidity and functional status.
In 1999, Hebert et al [10] reported the results of the
TRICC trial. Patients (n = 838) were randomized either to a
restrictive strategy (haemoglobin concentration maintained
between 70 and 90 g/l, with a trigger set at 70 g/l) or to a
liberal strategy (haemoglobin concentration maintained
between 100 and 120 g/l, with a trigger at 100 g/l). To
date, the TRICC trial is the only large study that has investi-
gated these parameters. The groups were comparable atbaseline. The average daily haemoglobin concentration
ranged from 85 ± 7.2 g/l in the restrictive group to
107 ± 7.3 g/l in the liberal group (P < 0.01). The average
number of transfusions was reduced by 52% in the restric-
tive group (2.6 ± 4.1 versus 5.6 ± 5.3 RBCs/patient;
P < 0.01). Cardiac events, primarily pulmonary oedema
and myocardial infarction, were more frequent in the liberal
strategy (P < 0.01; Table 1). On examination of composite
outcomes, the number of patients with multiorgan failure
was found to be substantially increased in both groups,
with the results being marginally better in the restrictive
strategy group (20.6% versus 26.0%; P = 0.07; Table 2).
Overall, the restrictive transfusion group showed a lower
30-day mortality (18.7% versus 23.3%; P = 0.11; Fig. 1).
Kaplan–Meier survival curves, however, were significantly
different in the subgroup of patients with an Acute Physiol-
ogy and Chronic Health Evaluation II score of 20 or less
(P = 0.02; Fig. 2). In addition, although 60-day mortality
(22.8% versus 26.5%; P = 0.23) and ICU mortality (13.9%
versus 16.2%; P = 0.29) were not statistically significant,
they did show a consistent trend in terms of absolute
values that favoured the restrictive strategy. The key obser-
vation from the TRICC trial is not that the restrictive strat-
egy is better, but rather that it is at worst equivalent to the
liberal strategy and at best superior to the liberal strategy.
Subgroups that are at increased risk from
anaemia
At this juncture, preclinical and clinical evidence support
the adoption of a more restrictive transfusion strategy in
most critically ill patients. However, there remain divergent
views regarding the risks and benefits of treating anaemia
in patients with cardiovascular disease. Laboratory-based
studies [68,69] suggest that patients with cardiovascular
disease may require higher haemoglobin concentrations to
maintain oxygen delivery in partially occluded or diseased
coronary arteries. Studies to demonstrate how anaemia
affects contractile function of the left ventricle have rarely
shown important effects above haemoglobin concentra-
tions of 70 g/l. Indeed, it is more important to address the
underlying pathophysiological causes of the acute coro-
nary syndrome with proven therapy such as aspirin and
b-blockers, rather than treating mild-to-moderate anaemia
as an initial step. If the effects of RBC transfusion were
either limited or increased then there would be no debate;
however, the use of allogeneic RBCs has been shown to
be associated with immunomodulation [12,47] and/or
alteration in the delivery of oxygen in the microcirculation
[70,71], resulting in increased rates of infections and
organ failure.
Few clinical studies have attempted to elucidate the risk :
benefit ratio of anaemia and transfusion in cardiac patients.
Two small RCTs [62,72] examined transfusion practice in
patients undergoing coronary artery bypass grafting, and
concluded that a conservative approach to the administra-
tion of RBCs may be safe. However, two recent cohort
studies suggested that anaemia may increase the risk of
mortality in critical illness [73] and following surgery in
patients with cardiovascular disease [74].
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Table 1
Outcomes from the TRICC trial
Restrictive transfusion  Liberal transfusion  Absolute difference  95% 
Outcome measure strategy strategy between groups* Confidence interval P
Mortality rates (n [%])
30-day 78 (18.7) 98 (23.3) 4.7 –0.84 to 10.2 0.11
60-day† 95 (22.8) 111 (26.5) 3.7 –2.1 to 9.5 0.23
ICU 56 (13.9) 68 (16.2) 2.3 –2.0 to 7.6 0.29
Hospital 93 (22.3) 118 (28.1) 5.8 –0.3 to 11.7 0.05
Organ dysfunction (mean ± standard deviation)
MOD score 8.3 ± 4.6 8.8 ± 4.4 0.5 –0.1 to 1.1 0.1
MOD score‡ 10.7 ± 7.5 11.8 ± 7.7 1.1 0.8 to 2.2 0.03
MOD score§ 3.2 ± 7.0 4.2 ± 7.4 1 0.1 to 2.0 0.04
Organ failure (n [%])
0 Failures 100 (23.9) 81 (19.3)
1 Failure 136 (32.5) 149 (35.6)
2 Failures 109 (26.1) 108 (26.0)
3 Failures 51 (12.2) 63 (15.0)
>3 Failures 22 (5.3) 18 (4.3) 1.8 –3.4 to 7.1 0.36
Duration of stay (mean ± standard deviation)
ICU (days) 11.0 ± 10.7 11.5 ± 11.3 0.5 –1.0 to 2.1 0.53
Hospital (days) 34.8 ± 19.5 35.5 ± 19.4 0.7 –1.9 to 3.4 0.58
There were 418 and 420 patients in the restrictive and liberal transfusion groups, respectively. *Difference calculated by subtracting mean values of
restrictive group from those of liberal group. †Three patients were lost to 60-day mortality rate; therefore n = 835. ‡Nonsurvivors are considered to have
all organs failing on date of death. §Changes in MOD score from baseline, while also incorporating adjustment for death. Data from Hébert et al [10].In a study of Jehovah’s Witnesses (a group that refuses
RBC transfusion on religious grounds) undergoing surgi-
cal procedures [74], it was noted that mortality was signifi-
cantly increased in patients with cardiac disease after a
decrease in haemoglobin levels from 100–110 g/l to
60–69 g/l. In that study, patients with no cardiac disease
and similar changes in haemoglobin levels showed no
increase in mortality, which is in accordance with the
results of the TRICC trial [10]. In the study by Hébert et al.
[73] of 4470 critically ill patients, a correlation between
Critical Care    Vol 5 No 2 Alvarez et al
Table 2
Complications that occurred during the patients’ stays in the ICU
Restrictive transfusion  Liberal transfusion  Absolute difference  95% 
Complication* strategy group (n [%]) strategy group (n [%]) between groups (%) Confidence interval† P
Cardiac 55 (13.2) 88 (21.0) 7.8 2.7 to 12.9 <0.01
Myocardial infarction 3 (0.7) 12 (2.9) 2.1 – 0.02
Pulmonary oedema 22 (5.3) 45 (10.7) 5.5 1.8 to 9.1 <0.01
Angina 5 (1.2) 9 (2.1) 0.9 – 0.28
Cardiac arrest 29 (6.9) 33 (7.9) 0.9 –2.6 to 4.5 0.6
Pulmonary 106 (25.4) 122 (29.1) 3.7 –2.3 to 9.7 0.22
ARDS 32 (7.7) 48 (11.4) 3.8 –0.2 to 7.8 0.06
Pneumonia 87 (20.8) 86 (20.5) –0.3 –5.8 to 5.1 0.92
Infectious 42 (10.1) 50 (11.9) 1.9 –2.4 to 6.1 0.38
Bacteraemia 30 (7.2) 40 (9.5) 2.3 –1.4 to 6.1 0.22
Line sepsis 21 (5.1) 17 (4.0) –1 –3.8 to 1.8 0.5
Septic shock 41(9.8) 29(6.9) –2.9 –6.7 to 0.8 0.13
Haematological‡ 10 (2.4) 10 (2.4) 0 –2.1 to 2.1 1
Gastrointestinal§ 13 (3.1) 19 (4.5) 1.4 –1.2 to 4.0 0.28
Neurological¶ 25 (6.0) 33 (7.9) 1.9 –1.6 to 5.3 0.28
Shock** 67 (16.0) 55 (13.1) –2.9 –7.7 to 1.8 0.23
Any complication 205 (49.0) 228 (54.3) 5.2 –1.5 to 12.0 0.12
There were 418 and 420 patients in the restrictive and liberal transfusion groups, respectively. *Patients may have had more than one type of
complication. †In some cases, the number of patients in a group was too small to allow calculation of the 95% confidence interval. ‡This category
includes transfusion reactions, haemolytic anaemia, disseminated intravascular coagulation and other blood dyscrasias. §This category includes
gastrointestinal bleeding, bowel perforation and ischaemic bowel syndrome. ¶This category includes cerebrovascular accidents and
encephalopathies. **This category includes hypovolaemic shock, cardiogenic shock and all other types of shock, except septic shock. ARDS, acute
respiratory distress syndrome. Data from Hébert et al [10].
Figure 1
Kaplan–Meier estimates of survival in the 30 days after admission to
the ICU in the restrictive and liberal transfusion strategy groups (all
patients). Data from Hébert et al [10].
Figure 2
Kaplan–Meier estimates of survival in the 30 days after admission to
the ICU in the restrictive and liberal transfusion strategy groups
(patients with APACHE II score £20). Data from Hébert et al [10].anaemia and mortality rates was observed. Those investi-
gators also found that the risk of anaemia appeared to
decrease with RBC transfusion in patients with cardiac
disease. In patients with cardiac disease, mortality
increased when haemoglobin concentrations were below
95 g/l, as compared with anaemic patients with other
diagnoses (55% versus 42%; P = 0.09). In the subgroup
of patients with cardiac disease, increasing haemoglobin
values in anaemic patients was associated with improved
survival (odds ratio 0.80 for each 10 g/l increase;
P = 0.012). One possible explanation for the discrepancy
between the TRICC trial and this observational study may
be that the attending physicians who recruited patients
into the study did not enter those patients who were con-
sidered to have severe cardiac disease.
Hébert et al. [73] sought to examine further whether a
restrictive transfusion strategy was at least as effective
as a liberal strategy in critically ill patients with cardiac
disease. In the subgroup of patients with cardiovascular
disease from the TRICC trial, those investigators sug-
gested that most haemodynamically stable critically ill
patients with cardiovascular disease may be transfused
when haemoglobin concentrations fall below 70 g/l, and
that the hemoglobin concentration should be maintained
between 70 and 90 g/l. Average daily haemoglobin con-
centrations were 85 ± 6.2 g/l in the restrictive transfu-
sion group and 103 ± 6.7 g/l in the liberal transfusion
group (P < 0.01). In the 357 patients with cardiovascular
disease, the 30-day mortality rate was 23% in the
restrictive transfusion group versus 23% in the liberal
group (95% confidence interval of the difference –8.4%
to 9.1%; P = 1.00). Other mortality rates, including 60-
day (26% versus 27%; P = 0.90), ICU (19% versus
16%; P = 0.49) and hospital mortality (27% versus
28%;  P = 0.81), were not significantly different between
groups. Kaplan–Meier survival curves comparing time to
death demonstrated similar trends in the two groups
(Fig. 3;  P = 0.98). The multiple organ dysfunction (MOD)
scores, during the entire study period, were also not sig-
nificantly different between groups (8.6 ± 4.9 versus
9.0 ± 4.4;  P = 0.40), but the change in MOD score from
baseline values was significantly lower in the restrictive
group than in the liberal group (0.2 ± 4.2 versus
1.3 ± 4.4;  P = 0.02).
Combined measures of morbidity and mortality, or com-
posite outcomes, were also examined. When all patients
who died were given a score of 24, the total MOD score
between groups was not different (P = 0.39), or were the
changes in MOD scores significantly different from base-
line (2.7 ± 6.9 versus 4.0 ± 7.3; P = 0.08). Among the
specific subset of cardiac patients with ischaemic heart
disease (n = 257), there were no discernible differences
in 30-day and 60-day as well as ICU mortality rates.
However, a nonsignificant (P = 0.3) decrease in overall
survival rate in the restrictive group was noted in those
patients with confirmed ischaemic heart disease, severe
peripheral vascular disease or severe comorbid cardiac
disease (Fig. 4).
In conclusion, a restrictive RBC transfusion strategy gen-
erally appears to be safe in most critically ill patients with
cardiovascular disease, with the possible exception of
patients experiencing acute myocardial infarction or unsta-
ble angina.
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Figure 3
Survival over 30 days in all cardiac patients in the restrictive and liberal
allogeneic RBC transfusion groups. This graph illustrates
Kaplan–Meier survival curves for all cardiac patients in both study
groups. There is no difference in mortality in patients in the restrictive
group (dashed line) as compared to the liberal group (solid line)
(P = 0.95).
Figure 4
Survival over 30 days in patients with ischemic heart disease in the
restrictive and liberal allogeneic RBC transfusion strategy groups.  This
graph illustrates Kaplan–Meier survival curves for all patients with
ischemic heart disease in both study groups. There is no difference in
mortality in patients in the restrictive group (dashed line) as compared
to the liberal group (solid line) (P = 0.30).Critical Care    Vol 5 No 2 Alvarez et al
Conclusion
The need to reduce the amount of allogeneic blood trans-
fusions in order to reduce the associated risks has been
firmly established. RBCs are associated with clinically
important immune suppression, and stored RBCs have
been shown to cause adverse microcirculatory effects that
result in increased organ failure.
The question for some time has been whether critically ill
patients are able to tolerate lower levels of haemoglobin
without deleterious effects, thus reducing the amount of
exposure to allogeneic transfusions. In the only large RCT,
Hébert et al [10] established that there was no difference
in mortality rates between restrictive and liberal transfu-
sion strategies in noncardiac, critically ill patients.
Although those investigators were able to show convinc-
ing trends that the liberal strategy may in fact be deleteri-
ous in terms of absolute values, statistical significance
was not achieved. However, the fact that no difference
between the two strategies was achieved is of great
importance, because this means that the total number of
transfusions can be reduced by approximately half without
any impact on mortality. In addition, these findings are
easily put into clinical practice. Although many questions
remain, the TRICC trial and many laboratory and clinical
studies have established that transfusing to normal
haemoglobin concentrations does not improve organ
failure and mortality in the critically ill patient. As such, a
restrictive transfusion strategy will reduce exposure to allo-
geneic transfusions, result in more efficient use of RBCs,
save blood overall, and decrease health care costs. 
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